US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRAWS PHARMA

2.16

-0.3200-12.90%

Post-market: 2.180.0200+0.93%16:39 EST

Volume:315.67K

Turnover:720.13K

Market Cap:17.26M

PE:-2.02

High:2.52

Open:2.50

Low:2.10

Close:2.48

52wk High:19.44

52wk Low:0.9700

Shares:7.99M

Float Shares:5.93M

Volume Ratio:1.37

T/O Rate:5.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0708

EPS(LYR):-35.2126

ROE:-1059.63%

ROA:-92.29%

PB:3.80

PE(LYR):-0.06

Loading ...

Overview Company News Filings

Traws Pharma Inc. Held Annual Shareholder Meeting

Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY

Traws Pharma posts $4.0 million net loss on zero revenue for Q3 2025

Traws Pharma Inc: Q3 EPS $-0.34

THOMSON REUTERS

Press Release: Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development

Chemdiv Extends Cmc Services Collaboration for Ratutrelvir, a Potential Best-in-Class Covid-19 Therapeutic Advancing in Phase 2 Clinical Trials

THOMSON REUTERS

Traws Pharma Launches Phase 2 Trial of Ritonavir-Free COVID-19 Antiviral Ratutrelvir

Traws Pharma Grants Stock Options to Executive Team

Traws Pharma Inc. Files Initial Beneficial Ownership Statement for Director John Harold Leaman

Traws Pharma Begins Phase 2 Trials of Ritonavir-Free COVID Treatment Ratutrelvir, Results Expected by Year-End 2025

Traws Pharma Inc -Top-Line Data From Both Trials Expected by Year-End 2025

THOMSON REUTERS

Traws Pharma Doses First Patient With Ratutrelvir in Phase 2 Covid Studies, Expects Results by Year-End 2025

THOMSON REUTERS

Traws Pharma Inc. Announces Date for Upcoming Annual Stockholders Meeting

Traws Pharma appoints John Leaman as independent director

Press Release: Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

BRIEF-Traws Pharma On September 9, Entered Asset Purchase Agreement With Virom - SEC Filing

Traws Pharma Inc - on September 9, Enters Asset Purchase Agreement With Virom - SEC Filing

THOMSON REUTERS

Traws Pharma Inc - Purchases Assets From Virom for $2.35 Mln in Cash - SEC Filing

THOMSON REUTERS

Traws Pharma Acquires Viriom's Antiviral Assets for $2.35 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TRAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":2.16,"timestamp":1764709200000,"preClose":2.48,"halted":0,"volume":315665,"hourTrading":{"tag":"盘后","latestPrice":2.18,"preClose":2.16,"latestTime":"16:39 EST","volume":6,"amount":13.060000200000001,"timestamp":1764711599906},"delay":0,"floatShares":5925700,"shares":7990867,"eps":-1.070813,"marketStatus":"Post-Mkt","change":-0.32,"latestTime":"12-02 17:42:40 EST","open":2.5,"high":2.5192,"low":2.1,"amount":720133.0671989999,"amplitude":0.169032,"askPrice":2.45,"askSize":32,"bidPrice":2.14,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-1.070813,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":2.48,"preHourTrading":{"tag":"盘前","latestPrice":2.45,"preClose":2.48,"latestTime":"09:18 EST","volume":54,"amount":135.0804924,"timestamp":1764685090536},"postHourTrading":{"tag":"盘后","latestPrice":2.18,"preClose":2.16,"latestTime":"16:39 EST","volume":6,"amount":13.060000200000001,"timestamp":1764711599906},"volumeRatio":1.373673,"impliedVol":1.6331,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","floatShares":5925700,"roa":"-92.29%","roe":"-1059.63%","lyrEps":-35.212551,"volumeRatio":1.373673,"shares":7990867,"dividePrice":0,"high":2.5192,"amplitude":0.169032,"preClose":2.48,"low":2.1,"week52Low":0.97,"pbRate":"3.80","psRate":"6.06","week52High":19.44,"institutionHeld":0,"latestPrice":2.16,"committee":-0.882353,"eps":-1.070813,"divideRate":0,"volume":315665,"delay":0,"ttmEps":-1.070813,"open":2.5,"prevYearClose":8.88,"prevWeekClose":2.7,"prevMonthClose":2.7,"prevQuarterClose":1.85,"fiveDayClose":2.43,"twentyDayClose":2.39,"sixtyDayClose":1.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TRAW","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.34},{"market":"US","date":"2025-08-14","symbol":"TRAW","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.11},{"market":"US","date":"2025-05-15","symbol":"TRAW","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":2.09},{"market":"US","date":"2025-03-31","symbol":"TRAW","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":95.66},{"market":"US","date":"2024-11-14","symbol":"TRAW","fiscalQuarterEnding":"2024/09","expectedEps":-6.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-8.81}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAW","date":"2025-12-01","current":-2.017159,"percent":0,"low":-1.621109,"twenty":-0.737219,"median":-0.111727,"eighty":-0.062783,"high":-0.033516,"avg":-0.354341,"sd":0.374122,"marketCap":21575340},"quantilePoints":[{"date":"2024-04-05","current":-0.930105,"twenty":-0.930105,"median":-0.930105,"eighty":-0.930105,"marketCap":17623624},{"date":"2024-04-12","current":-0.875242,"twenty":-0.899279,"median":-0.879971,"eighty":-0.87246,"marketCap":16584087},{"date":"2024-04-19","current":-0.774197,"twenty":-0.884701,"median":-0.859217,"eighty":-0.774642,"marketCap":14669484},{"date":"2024-04-26","current":-0.703922,"twenty":-0.875242,"median":-0.784323,"eighty":-0.745597,"marketCap":13337908},{"date":"2024-05-03","current":-0.713993,"twenty":-0.87246,"median":-0.75973,"eighty":-0.713993,"marketCap":13528735},{"date":"2024-05-10","current":-0.722239,"twenty":-0.859217,"median":-0.743093,"eighty":-0.71377,"marketCap":13684982},{"date":"2024-05-17","current":-0.7463,"twenty":-0.799236,"median":-0.738475,"eighty":-0.713993,"marketCap":13549821},{"date":"2024-05-24","current":-0.73457,"twenty":-0.794005,"median":-0.741761,"eighty":-0.718444,"marketCap":13336853},{"date":"2024-05-31","current":-0.675921,"twenty":-0.778515,"median":-0.736522,"eighty":-0.713681,"marketCap":12272014},{"date":"2024-06-07","current":-0.836261,"twenty":-0.794624,"median":-0.73457,"eighty":-0.711322,"marketCap":15183160},{"date":"2024-06-14","current":-0.873049,"twenty":-0.83888,"median":-0.740589,"eighty":-0.71288,"marketCap":15851082},{"date":"2024-06-21","current":-0.649387,"twenty":-0.836845,"median":-0.738475,"eighty":-0.709541,"marketCap":11790270},{"date":"2024-06-28","current":-0.62709,"twenty":-0.83835,"median":-0.738475,"eighty":-0.706993,"marketCap":11385454},{"date":"2024-07-05","current":-0.557395,"twenty":-0.836651,"median":-0.734469,"eighty":-0.698614,"marketCap":10120072},{"date":"2024-07-12","current":-0.483661,"twenty":-0.814046,"median":-0.728873,"eighty":-0.672205,"marketCap":8781358},{"date":"2024-07-15","current":-0.554747,"twenty":-0.806641,"median":-0.726171,"eighty":-0.663181,"marketCap":10071990},{"date":"2024-08-02","current":-0.532446,"twenty":-0.799236,"median":-0.724978,"eighty":-0.649387,"marketCap":9667086},{"date":"2024-08-09","current":-0.491259,"twenty":-0.797102,"median":-0.722239,"eighty":-0.600613,"marketCap":8919304},{"date":"2024-08-16","current":-0.066488,"twenty":-0.794005,"median":-0.718444,"eighty":-0.532446,"marketCap":9112137},{"date":"2024-08-23","current":-0.065565,"twenty":-0.774642,"median":-0.71377,"eighty":-0.508851,"marketCap":8985580},{"date":"2024-08-30","current":-0.06743,"twenty":-0.774197,"median":-0.709986,"eighty":-0.494812,"marketCap":9241226},{"date":"2024-09-06","current":-0.06538,"twenty":-0.762623,"median":-0.702951,"eighty":-0.490604,"marketCap":8960268},{"date":"2024-09-13","current":-0.062794,"twenty":-0.758648,"median":-0.694503,"eighty":-0.071087,"marketCap":8605907},{"date":"2024-09-20","current":-0.057254,"twenty":-0.751084,"median":-0.683063,"eighty":-0.068232,"marketCap":7846562},{"date":"2024-09-27","current":-0.081301,"twenty":-0.74722,"median":-0.649387,"eighty":-0.067774,"marketCap":11142278},{"date":"2024-10-04","current":-0.073971,"twenty":-0.746382,"median":-0.624791,"eighty":-0.068232,"marketCap":10137646},{"date":"2024-10-11","current":-0.065174,"twenty":-0.745738,"median":-0.557395,"eighty":-0.067596,"marketCap":8932088},{"date":"2024-10-18","current":-0.062642,"twenty":-0.744673,"median":-0.543597,"eighty":-0.067316,"marketCap":8585034},{"date":"2024-10-25","current":-0.111702,"twenty":-0.743234,"median":-0.515682,"eighty":-0.066488,"marketCap":15308680},{"date":"2024-10-31","current":-0.109715,"twenty":-0.741526,"median":-0.508851,"eighty":-0.066652,"marketCap":15036392},{"date":"2024-11-08","current":-0.111592,"twenty":-0.739321,"median":-0.498158,"eighty":-0.06682,"marketCap":15293553},{"date":"2024-11-15","current":-0.123204,"twenty":-0.736132,"median":-0.492107,"eighty":-0.067201,"marketCap":16884930},{"date":"2024-11-22","current":-0.096923,"twenty":-0.734509,"median":-0.489621,"eighty":-0.06743,"marketCap":13645248},{"date":"2024-11-29","current":-0.098427,"twenty":-0.734469,"median":-0.48099,"eighty":-0.067496,"marketCap":13857037},{"date":"2024-12-06","current":-0.108407,"twenty":-0.733312,"median":-0.130241,"eighty":-0.067596,"marketCap":15262104},{"date":"2024-12-13","current":-0.104014,"twenty":-0.729414,"median":-0.121316,"eighty":-0.067685,"marketCap":14643681},{"date":"2024-12-20","current":-0.114642,"twenty":-0.725217,"median":-0.114642,"eighty":-0.068025,"marketCap":16139817},{"date":"2024-12-27","current":-0.244993,"twenty":-0.723719,"median":-0.117501,"eighty":-0.068353,"marketCap":34491315},{"date":"2025-01-03","current":-0.186323,"twenty":-0.723452,"median":-0.123204,"eighty":-0.068427,"marketCap":26231553},{"date":"2025-01-10","current":-0.173429,"twenty":-0.722482,"median":-0.130241,"eighty":-0.069344,"marketCap":24416220},{"date":"2025-01-17","current":-0.146996,"twenty":-0.721141,"median":-0.147157,"eighty":-0.069786,"marketCap":20694789},{"date":"2025-01-24","current":-0.13797,"twenty":-0.719413,"median":-0.140763,"eighty":-0.070056,"marketCap":19424056},{"date":"2025-01-31","current":-0.156666,"twenty":-0.718444,"median":-0.146996,"eighty":-0.070643,"marketCap":22056288},{"date":"2025-02-07","current":-0.178157,"twenty":-0.715773,"median":-0.153981,"eighty":-0.07105,"marketCap":25081842},{"date":"2025-02-14","current":-0.173739,"twenty":-0.713859,"median":-0.157526,"eighty":-0.072709,"marketCap":24459897},{"date":"2025-02-21","current":-0.121618,"twenty":-0.713592,"median":-0.156666,"eighty":-0.073848,"marketCap":17121928},{"date":"2025-02-28","current":-0.087129,"twenty":-0.71288,"median":-0.149414,"eighty":-0.074131,"marketCap":12266456},{"date":"2025-03-07","current":-0.070533,"twenty":-0.710432,"median":-0.144632,"eighty":-0.071013,"marketCap":9929988},{"date":"2025-03-14","current":-0.07157,"twenty":-0.706225,"median":-0.135069,"eighty":-0.071013,"marketCap":10076017},{"date":"2025-03-21","current":-0.074682,"twenty":-0.703145,"median":-0.130241,"eighty":-0.070984,"marketCap":10514105},{"date":"2025-03-28","current":-0.066643,"twenty":-0.70173,"median":-0.123448,"eighty":-0.070533,"marketCap":9382378},{"date":"2025-04-04","current":-0.066422,"twenty":-0.698614,"median":-0.121618,"eighty":-0.069679,"marketCap":11060862},{"date":"2025-04-11","current":-0.053321,"twenty":-0.692996,"median":-0.117957,"eighty":-0.068372,"marketCap":8879132},{"date":"2025-04-17","current":-0.060633,"twenty":-0.690629,"median":-0.115407,"eighty":-0.067596,"marketCap":10096842},{"date":"2025-04-25","current":-0.046618,"twenty":-0.687348,"median":-0.111751,"eighty":-0.066971,"marketCap":7762898},{"date":"2025-05-02","current":-0.042961,"twenty":-0.674063,"median":-0.111618,"eighty":-0.066488,"marketCap":7154043},{"date":"2025-05-09","current":-0.042657,"twenty":-0.663181,"median":-0.111481,"eighty":-0.065417,"marketCap":7103306},{"date":"2025-05-16","current":-0.033516,"twenty":-0.647743,"median":-0.11053,"eighty":-0.064788,"marketCap":5581169},{"date":"2025-05-23","current":-0.045648,"twenty":-0.63835,"median":-0.110157,"eighty":-0.064588,"marketCap":6392975},{"date":"2025-05-30","current":-0.055226,"twenty":-0.62709,"median":-0.109384,"eighty":-0.063348,"marketCap":7734397},{"date":"2025-06-06","current":-0.058802,"twenty":-0.622492,"median":-0.108696,"eighty":-0.062794,"marketCap":8235186},{"date":"2025-06-13","current":-0.071516,"twenty":-0.600613,"median":-0.107668,"eighty":-0.063175,"marketCap":10015767},{"date":"2025-06-20","current":-0.065556,"twenty":-0.566039,"median":-0.107023,"eighty":-0.063313,"marketCap":9181119},{"date":"2025-06-27","current":-0.056815,"twenty":-0.557298,"median":-0.10387,"eighty":-0.062794,"marketCap":7956970},{"date":"2025-07-03","current":-0.05761,"twenty":-0.555758,"median":-0.101756,"eighty":-0.062399,"marketCap":8068256},{"date":"2025-07-11","current":-0.062378,"twenty":-0.541366,"median":-0.099933,"eighty":-0.061976,"marketCap":8735974},{"date":"2025-07-18","current":-0.064364,"twenty":-0.529937,"median":-0.097675,"eighty":-0.061583,"marketCap":9014190},{"date":"2025-07-25","current":-0.064761,"twenty":-0.520715,"median":-0.095947,"eighty":-0.061819,"marketCap":9069833},{"date":"2025-08-01","current":-0.061186,"twenty":-0.513446,"median":-0.092228,"eighty":-0.061583,"marketCap":8569045},{"date":"2025-08-08","current":-0.058802,"twenty":-0.510093,"median":-0.087897,"eighty":-0.061164,"marketCap":8235186},{"date":"2025-08-15","current":-0.50579,"twenty":-0.507369,"median":-0.086481,"eighty":-0.061164,"marketCap":9014190},{"date":"2025-08-22","current":-0.546969,"twenty":-0.527596,"median":-0.090759,"eighty":-0.061186,"marketCap":9748084},{"date":"2025-08-29","current":-0.562823,"twenty":-0.55008,"median":-0.094773,"eighty":-0.061424,"marketCap":10030637},{"date":"2025-09-05","current":-0.65993,"twenty":-0.557347,"median":-0.096218,"eighty":-0.061583,"marketCap":11761275},{"date":"2025-09-12","current":-0.717402,"twenty":-0.561238,"median":-0.098427,"eighty":-0.061583,"marketCap":12785530},{"date":"2025-09-19","current":-0.81649,"twenty":-0.587397,"median":-0.100444,"eighty":-0.06174,"marketCap":14551487},{"date":"2025-09-26","current":-0.745146,"twenty":-0.633715,"median":-0.10251,"eighty":-0.061976,"marketCap":13279998},{"date":"2025-10-03","current":-0.721365,"twenty":-0.66395,"median":-0.104979,"eighty":-0.061978,"marketCap":12856168},{"date":"2025-10-10","current":-1.240589,"twenty":-0.692996,"median":-0.107234,"eighty":-0.06201,"marketCap":22109784},{"date":"2025-10-17","current":-1.058266,"twenty":-0.706225,"median":-0.108145,"eighty":-0.062128,"marketCap":18860423},{"date":"2025-10-24","current":-1.051562,"twenty":-0.713592,"median":-0.109053,"eighty":-0.062292,"marketCap":18740938},{"date":"2025-10-31","current":-1.05556,"twenty":-0.718444,"median":-0.109936,"eighty":-0.06243,"marketCap":18812196},{"date":"2025-11-07","current":-0.809663,"twenty":-0.722967,"median":-0.110382,"eighty":-0.062562,"marketCap":14429809},{"date":"2025-11-14","current":-0.707705,"twenty":-0.726854,"median":-0.111401,"eighty":-0.062695,"marketCap":12612722},{"date":"2025-11-21","current":-1.284879,"twenty":-0.733984,"median":-0.111592,"eighty":-0.062775,"marketCap":17100455},{"date":"2025-11-28","current":-1.621109,"twenty":-0.736689,"median":-0.111702,"eighty":-0.062779,"marketCap":21575340},{"date":"2025-12-01","current":-1.621109,"twenty":-0.737219,"median":-0.111727,"eighty":-0.062783,"marketCap":21575340}],"updateTime":1764715356362},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2587815730","title":"Traws Pharma Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2587815730","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587815730?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:31","pubTimestamp":1764365493,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. held its annual meeting of stockholders on November 21, 2025. At the meeting, all nominated directors were elected to the board. Stockholders also approved an amendment and restatement of the company's incentive compensation plan, which increases the number of shares reserved for issuance and extends the plan's term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL6c27Q5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2583456223","title":"Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583456223","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583456223?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:17","pubTimestamp":1763036250,"startTime":"0","endTime":"0","summary":"Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48830377/traws-pharma-q3-eps-0-34-up-from-8-81-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2583562862","title":"Traws Pharma posts $4.0 million net loss on zero revenue for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562862","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562862?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:03","pubTimestamp":1763035425,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. reported a net loss of $4.0 million, or $0.34 per basic and diluted common share, for the quarter ended September 30, 2025, compared to a net loss of $8.5 million, or $1.49 per share, for the same period in 2024. Revenue for the quarter was zero, down from $57,000 in the prior year period. Research and development expenses totaled $2.3 million, down from $5.1 million, while general and administrative expenses were $1.7 million, compared to $3.5 million in the third quarter of 2024. The company had 8.0 million shares of common stock outstanding as of November 10, 2025. During the period, Traws Pharma acquired intellectual property and other assets associated with a pyrrolidine antiviral compound from Viriom, Inc. for $2.6 million and continued Phase 2 studies for ratutrelvir, an investigational oral protease inhibitor for acute and long COVID, with top-line data expected by year end.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7QVp4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2583562440","title":"Traws Pharma Inc: Q3 EPS $-0.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562440?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA2XBV93:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2583556471","title":"Press Release: Traws Pharma Reports Third Quarter 2025 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583556471","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583556471?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035200,"startTime":"0","endTime":"0","summary":"Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end. NEWTOWN, Pa., Nov. 13, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs.Ratutrelvir : Potential best-in-class therapy to minimize the risk of viral rebound and Long COVID. A ritonavir-independent investigational oral Main protease  inhibitor designed to be administered as a single dose, with potential for once-daily, 10-day dosing. -- Intended Indication: Treatment of acute COVID infection, with potential. to reduce the risk of COVID rebound and Long COVID, including in. -- U.S. Market Opportunity: Estimated to be a multi-billion dollar. study to evaluat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4007","BK4218","BK4181","PK","R","TRAW","BK4022"],"gpt_icon":0},{"id":"2579124992","title":"Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2579124992","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579124992?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:00","pubTimestamp":1761840030,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has extended its collaboration with ChemDiv for Chemistry, Manufacturing and Controls  services to support the clinical development of ratutrelvir, an oral antiviral treatment for COVID-19 currently in Phase 2 clinical trials. The updated agreement includes CMC process research and scale-up for manufacturing, medicinal chemistry support, translational pharmacology services, and clinical pharmacology consulting. Additionally, Expert Systems has extended its contract with Traws Pharma to provide predictive safety pharmacology services using its AI-enabled platform to support further clinical development of ratutrelvir.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL8lBVYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4127","IE00B66KJ199.SGD","BK4007","TRAW","IE0031619046.USD","RILY"],"gpt_icon":0},{"id":"2579124542","title":"Chemdiv Extends Cmc Services Collaboration for Ratutrelvir, a Potential Best-in-Class Covid-19 Therapeutic Advancing in Phase 2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2579124542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579124542?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:00","pubTimestamp":1761840000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUABCT4KW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2577341348","title":"Traws Pharma Launches Phase 2 Trial of Ritonavir-Free COVID-19 Antiviral Ratutrelvir","url":"https://stock-news.laohu8.com/highlight/detail?id=2577341348","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577341348?lang=en_us&edition=fundamental","pubTime":"2025-10-23 06:40","pubTimestamp":1761172846,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced the initiation of Phase 2 clinical studies for Ratutrelvir , a novel oral antiviral developed for newly diagnosed COVID-19 patients. Ratutrelvir is designed as a ritonavir-free treatment and aims to address the needs of populations who are ineligible for current standard-of-care antiviral options, such as PAXLOVID. The drug has shown broad-spectrum in vitro activity against multiple SARS-CoV-2 strains and maintains high potency without the need for ritonavir co-administration, potentially reducing drug-drug interactions. In Phase 1 multiple ascending dose studies, the daily oral regimen demonstrated sustained plasma concentrations above key efficacy thresholds for a 10-day course and was reported to have an excellent safety profile. The results of the Phase 2 clinical study have not yet been presented and will be announced in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL5xTkK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2576064376","title":"Traws Pharma Grants Stock Options to Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064376","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064376?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:04","pubTimestamp":1760735069,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has approved new stock option grants for its executive officers. On October 12, 2025, the company's Compensation Committee granted options to purchase shares of common stock at an exercise price of $3.01 per share. The grants include 64,839 options to Chief Executive Officer Iain Dukes, 32,406 options each to Chief Financial Officer Charles Parker, Chief Science Officer, Virology C. David Pauza, and Chief Medical Officer Robert Redfield, and 22,435 options to Chief Operating Officer Nikolay Savchuk. The options have a ten-year term and will vest in full on the first anniversary of the grant date, provided the recipients remain with the company. These options were issued under Traws Pharma's Amended and Restated 2021 Incentive Compensation Plan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL4l28KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2575257182","title":"Traws Pharma Inc. Files Initial Beneficial Ownership Statement for Director John Harold Leaman","url":"https://stock-news.laohu8.com/highlight/detail?id=2575257182","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575257182?lang=en_us&edition=fundamental","pubTime":"2025-10-15 07:01","pubTimestamp":1760482906,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names John Harold Leaman as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL83Jl9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2575291499","title":"Traws Pharma Begins Phase 2 Trials of Ritonavir-Free COVID Treatment Ratutrelvir, Results Expected by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575291499","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575291499?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:02","pubTimestamp":1760439744,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced the initiation of two Phase 2 clinical studies evaluating ratutrelvir, a ritonavir-free antiviral treatment for COVID-19. The first study is a non-inferiority trial comparing ratutrelvir to PAXLOVID, assessing safety, efficacy, rates of disease rebound, and incidence of Long COVID. The second is a single-arm trial evaluating safety and efficacy in patients who are ineligible for PAXLOVID, a group considered at higher risk for poor outcomes and with limited treatment options. Top-line data from both trials are expected by year-end 2025. No study results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLWl1Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2575993291","title":"Traws Pharma Inc -Top-Line Data From Both Trials Expected by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575993291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575993291?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA2KGX8F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2575291552","title":"Traws Pharma Doses First Patient With Ratutrelvir in Phase 2 Covid Studies, Expects Results by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575291552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575291552?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA2KGX8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2574196972","title":"Traws Pharma Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574196972","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574196972?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:17","pubTimestamp":1759954632,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced that it will hold its 2025 Annual Meeting of Stockholders on November 21, 2025. The meeting will be conducted virtually. Stockholders will have the opportunity to vote on proposals set forth by the company's Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL3fHwRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2573671086","title":"Traws Pharma appoints John Leaman as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671086","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671086?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:37","pubTimestamp":1759750637,"startTime":"0","endTime":"0","summary":"Traws Pharma (TRAW) announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-appoints-john-leaman-as-independent-director-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-appoints-john-leaman-as-independent-director-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2573679985","title":"Press Release: Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2573679985","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573679985?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:00","pubTimestamp":1759748400,"startTime":"0","endTime":"0","summary":"NEWTOWN, Pa., Oct. 06, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws' Board of Directors  has eliminated the interim notation of its key executives Iain Dukes and Charles Parker, who are now Chief Executive Officer and Chief Financial Officer, respectively.\"Dr. Leaman brings more than a decade of experience in finance, M&A and corporate strategy, and we are excited to welcome him to our Board of Directors. In addition, eliminating the interim title of our key executive officers indicates the full support of them by the Board,\" said Jack E. Stover, Chairman of Traws Pharma.\"I am thrilled to join Traws' Board of Directors as the Company progresses with its lead anti-viral product candidate, ratutrelvir, for CO","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4196","BK4007","MD","BK4218","PK","BK4181"],"gpt_icon":0},{"id":"2567904447","title":"BRIEF-Traws Pharma On September 9, Entered Asset Purchase Agreement With Virom - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2567904447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567904447?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:54","pubTimestamp":1757710495,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma On September 9, Entered Asset Purchase Agreement With Virom - SEC FilingSept 12  - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC -  ON SEPTEMBER 9, ENTERS ASSET PURCHASE AGREEMENT WITH VIROM - SEC FILINGTRAWS PHARMA INC - PURCHASES ASSETS FROM VIROM FOR $2.35 MILLION IN CASH - SEC FILINGSource text: [ID:n0001104659-25-089564]Further company coverage: TRAW.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nFWN3UZ0FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2567904342","title":"Traws Pharma Inc -  on September 9, Enters Asset Purchase Agreement With Virom - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2567904342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567904342?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:35","pubTimestamp":1757709343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nFWN3UZ0FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2567490434","title":"Traws Pharma Inc - Purchases Assets From Virom for $2.35 Mln in Cash - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2567490434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567490434?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:35","pubTimestamp":1757709343,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nFWN3UZ0FR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2567879904","title":"Traws Pharma Acquires Viriom's Antiviral Assets for $2.35 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2567879904","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567879904?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:34","pubTimestamp":1757709278,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced the acquisition of certain assets from Virom, Inc. through an Asset Purchase Agreement dated September 9, 2025. The $2.35 million transaction includes the purchase of intellectual property, patents, and other assets related to a pyrrolidine antiviral compound and its associated program pipeline. The acquisition, approved by Traws Pharma's Audit Committee and Board of Directors, also incorporates a third-party license agreement and related regulatory filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDLMRcW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}